Noom Launches Microdose GLP-1 Program for Preventive Health and Longevity
核心洞察
Noom (搜索) has launched the Proactive Health Microdose GLP-1Rx program, combining low-dose GLP-1 (搜索) medications with behavioral support and biomarker testing for preventive health.
The program targets individuals with BMI 21 or higher, using doses only 25% of traditional starting doses to address metabolic health before disease develops.
The comprehensive approach includes 17 biomarker tests every four months to track cardiovascular, metabolic, and hormonal health markers including HbA1c (搜索) and inflammation indicators.
Digital health platform Noom (搜索) has announced the launch of its Proactive Health Microdose GLP-1Rx program, marking a significant expansion into preventive medicine and longevity health. The first-of-its-kind program integrates microdosed GLP-1 (搜索) medications with behavioral coaching and comprehensive biomarker testing to address metabolic health before chronic disease (搜索) develops.
Addressing Suboptimal Health Before Disease Onset
The program targets a critical gap in preventive healthcare, as Dr. Jeffrey Egler, Noom (搜索)'s Chief Medical Officer, explains: "Most Americans are living with suboptimal health — and their blood biomarkers show it. That eventually manifests as chronic disease (搜索)." According to Egler, roughly three in four adults in midlife are living with at least one chronic health condition, with only one in eight adults meeting criteria for optimal metabolic health.
The clinical rationale centers on early intervention for cardiovascular risk. A Harvard-led study cited by Noom (搜索) found a 29% increase in coronary heart disease (搜索) risk for each 0.5-point increase in HbA1c (搜索) above 5.0%. "Someone with an HbA1c of 5.6% may think they're 'in-range,' but their cardiometabolic risk is already meaningfully elevated," Egler noted.
Three-Pillar Approach to Metabolic Health
The Proactive Health Microdose program combines three core components:
Microdose GLP-1 (搜索) Medication: Eligible patients receive personalized, small doses delivered directly to their homes. The starting dose represents only 25% of the lowest starting dose used in Noom (搜索)'s other programs, with personalized titration and safety guardrails.
Comprehensive Biomarker Testing: Members receive at-home test kits every four months featuring 17 advanced lab markers. These include newer cardiovascular predictors like ApoB (搜索) and Lp(a) (搜索), HbA1c (搜索) for blood sugar monitoring, high-sensitivity C-reactive protein (hs-CRP (搜索)) for inflammation, and hormonal markers including DHEA-S, testosterone, and estradiol.
Digital Behavioral Support: The Noom (搜索) Longevity Companion app provides daily habit-building tools, with 40% of monthly active microdose members using it daily for workouts, meal logging, step tracking, and body composition monitoring.
Expanded Access and Real-World Evidence
The program extends GLP-1 (搜索) access to individuals with BMI 21 or higher, representing the vast majority of US adults and expanding beyond traditional clinical obesity (搜索) criteria. This builds on Noom (搜索)'s initial microdose program launched in August for individuals with BMI 25 or higher.
Noom (搜索)'s real-world data demonstrates the synergistic effects of combining medication with behavioral intervention. Members in the top quartile of engagement lose 50% more weight on average than those in the bottom quartile after eight weeks. The platform consistently observes higher weekly app usage among members in GLP-1 (搜索) programs compared to those in weight-only programs.
"GLP-1s can lower food noise and may boost self-efficacy for health," said Noom (搜索) CEO Geoff Cook. "Action produces results, results fuel motivation, and motivation transforms identity. Health becomes habit, not effort."
Advanced Biomarker Monitoring
The program's biomarker testing addresses key longevity and metabolic health indicators often overlooked in routine care. The 17-marker panel includes:
- Cardiovascular markers: ApoB and Lp(a), described as "newer heart-disease predictors not often tested by PCPs"
- Metabolic indicators: HbA1c for blood sugar control and early prediabetes identification
- Inflammation markers: hs-CRP as a predictor of "silent" inflammation linked to cardiovascular risk
- Hormonal balance: DHEA-S, testosterone, and estradiol for age-related changes
- Nutritional status: Vitamin D and B12 levels
Members use the Tasso+ device for "simple, virtually painless sample collection," with results appearing in the Noom (搜索) app within one week as actionable insights.
Addressing Medication Discontinuation
The program directly addresses a critical challenge in GLP-1 (搜索) therapy: discontinuation rates reaching as high as 92%. "Most people eventually stop taking a GLP-1, which means medication alone is not enough," the company noted. By pairing medication with sustained behavior change, Noom (搜索) aims to maintain health benefits beyond the medication period.
"GLP-1s are not a shortcut — they're the spark," Dr. Egler explained. "They open the door for change, but actively walking through that door is what makes the transformation last."
Preventive Health Model
The program addresses a significant diagnostic gap, with CDC estimates indicating 80% of US adults with prediabetes (搜索) remain undiagnosed and unaware. The Proactive Health Microdose program aims to break this cycle through earlier detection and intervention.
"The old healthcare model waited for disease and treated symptoms," said Dr. Egler. "The new era is proactive — integrating biology, psychology, and technology to prevent disease before it starts."
The program is available to eligible Noom (搜索) members for $149 per month, positioning preventive GLP-1 (搜索) therapy as an accessible intervention for metabolic health optimization before clinical disease develops.